首页 > 最新文献

Clinical and Investigative Medicine最新文献

英文 中文
Hydrocortisone Combined with Vitamin C and Thiamine in the Treatment of Sepsis/Septic Shock: A Systematic Review with Meta-Analysis and Trial Sequential Analysis. 氢化可的松联合维生素C和硫胺素治疗败血症/感染性休克:荟萃分析和试验序列分析的系统综述。
IF 0.8 4区 医学 Q3 Medicine Pub Date : 2023-03-26 DOI: 10.25011/cim.v46i1.40275
Difan Lu, Wenchao Mao

Background: This study explored the efficacy of hydrocortisone combined with vitamin C and thiamine (HVT) in the treatment of sepsis/septic shock.

Methods: PubMed, EMBASE and Web of Science were searched (establishment of the database to October 31, 2022). The meta-analysis included randomized controlled trials (RCTs); comparing the efficacy of HVT regimen and placebo in the treatment of sepsis/septic shock. The Cochrane Handbook for Systematic Reviews of Interventions was used to assess the risk of bias. The Review Manager 5.4 software was used for meta-analysis, and the relative risk (RR), mean difference (MD) and 95% confidence intervals (CI) were then determined. Trial sequential analysis (TSA) was then conducted.

Results: Eight RCTs with 1,572 patients were identified. Meta-analysis showed that HVT regimen did not reduce all-cause (RR=0.96, 95% CI: 0.83 - 1.11, P=0.60), hospital (RR=1.03, 95% CI: 0.83 - 1.27, P=0.80) or intensive care unit (ICU) mortalities (RR=1.05, 95% CI: 0.86 - 1.28, P=0.65). Furthermore, there was no significant difference in the change of sequential organ failure assessment score, length of ICU stay, length of hospital stay, duration of the use of vasopressors, incidence of acute kidney injury and ventilator-free days between HVT and control groups. TSA showed that more trials are needed to confirm the results.

Conclusions: HVT regimen did not reduce the mortality of patients with sepsis/septic shock and was not associated with a significant improvement in outcomes. The TSA result showed that more RCTs with high quality and large sample sizes are needed to further confirm the results.

背景:本研究探讨氢化可的松联合维生素C和硫胺素(HVT)治疗脓毒症/感染性休克的疗效。方法:检索PubMed、EMBASE和Web of Science(建库至2022年10月31日)。meta分析包括随机对照试验(RCTs);比较HVT方案和安慰剂治疗败血症/感染性休克的疗效。采用Cochrane干预措施系统评价手册评估偏倚风险。采用Review Manager 5.4软件进行meta分析,确定相对危险度(RR)、平均差(MD)和95%置信区间(CI)。然后进行试验序列分析(TSA)。结果:共纳入8项随机对照试验,共1572例患者。荟萃分析显示,HVT方案并没有降低全因死亡率(RR=0.96, 95% CI: 0.83 - 1.11, P=0.60)、住院死亡率(RR=1.03, 95% CI: 0.83 - 1.27, P=0.80)或重症监护病房死亡率(RR=1.05, 95% CI: 0.86 - 1.28, P=0.65)。HVT组与对照组在序贯脏器功能衰竭评分、ICU住院时间、住院时间、血管加压药使用时间、急性肾损伤发生率、无呼吸机天数的变化无显著差异。运输安全管理局表示,需要更多的试验来证实这一结果。结论:HVT方案并没有降低脓毒症/感染性休克患者的死亡率,也没有显著改善预后。TSA结果表明,需要更多高质量、大样本量的rct来进一步证实结果。
{"title":"Hydrocortisone Combined with Vitamin C and Thiamine in the Treatment of Sepsis/Septic Shock: A Systematic Review with Meta-Analysis and Trial Sequential Analysis.","authors":"Difan Lu,&nbsp;Wenchao Mao","doi":"10.25011/cim.v46i1.40275","DOIUrl":"https://doi.org/10.25011/cim.v46i1.40275","url":null,"abstract":"<p><strong>Background: </strong>This study explored the efficacy of hydrocortisone combined with vitamin C and thiamine (HVT) in the treatment of sepsis/septic shock.</p><p><strong>Methods: </strong>PubMed, EMBASE and Web of Science were searched (establishment of the database to October 31, 2022). The meta-analysis included randomized controlled trials (RCTs); comparing the efficacy of HVT regimen and placebo in the treatment of sepsis/septic shock. The Cochrane Handbook for Systematic Reviews of Interventions was used to assess the risk of bias. The Review Manager 5.4 software was used for meta-analysis, and the relative risk (RR), mean difference (MD) and 95% confidence intervals (CI) were then determined. Trial sequential analysis (TSA) was then conducted.</p><p><strong>Results: </strong>Eight RCTs with 1,572 patients were identified. Meta-analysis showed that HVT regimen did not reduce all-cause (RR=0.96, 95% CI: 0.83 - 1.11, P=0.60), hospital (RR=1.03, 95% CI: 0.83 - 1.27, P=0.80) or intensive care unit (ICU) mortalities (RR=1.05, 95% CI: 0.86 - 1.28, P=0.65). Furthermore, there was no significant difference in the change of sequential organ failure assessment score, length of ICU stay, length of hospital stay, duration of the use of vasopressors, incidence of acute kidney injury and ventilator-free days between HVT and control groups. TSA showed that more trials are needed to confirm the results.</p><p><strong>Conclusions: </strong>HVT regimen did not reduce the mortality of patients with sepsis/septic shock and was not associated with a significant improvement in outcomes. The TSA result showed that more RCTs with high quality and large sample sizes are needed to further confirm the results.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9804296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Efficacy of Mesenchymal Stem Cell Therapy on Lupus Nephritis and Renal Function in Systemic Lupus Erythematosus: A Meta-Analysis. 间充质干细胞治疗对系统性红斑狼疮患者狼疮肾炎和肾功能的疗效:荟萃分析。
IF 0.8 4区 医学 Q3 Medicine Pub Date : 2023-03-26 DOI: 10.25011/cim.v46i1.39561
Yang Xia, Hua Ye, Kejia Li, Bairu Shi, Xian Sun, Jiajun Wu

Purpose: The purpose of this meta-analysis is to determine the efficacy of mesenchymal stromal/stem cell (MSC) transplantation therapy on lupus nephritis (LN) and renal function of patients with systemic lupus erythematosus (SLE).

Methods: Articles that reported the data of MSC therapy on the renal function as well as disease activity of LN in patients with SLE were searched in PubMed, Web of Science, Embase and the Cochrane Library. Mean difference for disease activity and laboratory parameters were pooled to evaluate the efficacy of MSC, and incidence was pooled for clinical remission, death and severe adverse event.

Results: A total of 12 studies with 586 patients were included. The disease activity indices, including SLEDAI and BILAG, were significantly decreased within 12 months after MSC therapy (P< 0.05). Laboratory parameters for renal function and disease control including estimated glomerular filtration rate, creatinine, blood urea nitrogen, complement C3, albumin and urine protein, were also significantly improved after therapy. The pooled rate of clinical remission at 12 months was 28.1% and the total rate during follow-up was 33.7%. The pooled rate of death at 12 months was 5.2% and the total rate during follow-up was 5.5%. Severe adverse events were rare and not associated with the treatment of MSC.

Conclusions: This is the first meta-analysis that focuses on the effect of MSC on LN and renal function of patients with SLE, and the results shows a favorable safety profile and encouraging results of MSC for improving the disease activity of LN as well as the renal function of SLE patients.

目的:本荟萃分析的目的是确定间充质基质/干细胞(MSC)移植治疗对系统性红斑狼疮(SLE)患者狼疮性肾炎(LN)和肾功能的疗效。方法:检索PubMed、Web of Science、Embase、Cochrane图书馆中报道MSC治疗对SLE患者肾功能及LN疾病活动度影响的文章。汇总疾病活动性和实验室参数的平均差异来评估MSC的疗效,并汇总临床缓解、死亡和严重不良事件的发生率。结果:共纳入12项研究,586例患者。MSC治疗后12个月内,SLEDAI、BILAG等疾病活动度指标均显著降低(P< 0.05)。治疗后,肾功能和疾病控制的实验室参数包括肾小球滤过率、肌酐、血尿素氮、补体C3、白蛋白和尿蛋白也有显著改善。12个月临床总缓解率为28.1%,随访总缓解率为33.7%。12个月合并死亡率为5.2%,随访期间总死亡率为5.5%。严重不良事件罕见,与MSC治疗无关。结论:这是首个关注MSC对SLE患者LN和肾功能影响的荟萃分析,结果显示MSC在改善LN疾病活动性和SLE患者肾功能方面具有良好的安全性和令人鼓舞的结果。
{"title":"Efficacy of Mesenchymal Stem Cell Therapy on Lupus Nephritis and Renal Function in Systemic Lupus Erythematosus: A Meta-Analysis.","authors":"Yang Xia,&nbsp;Hua Ye,&nbsp;Kejia Li,&nbsp;Bairu Shi,&nbsp;Xian Sun,&nbsp;Jiajun Wu","doi":"10.25011/cim.v46i1.39561","DOIUrl":"https://doi.org/10.25011/cim.v46i1.39561","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this meta-analysis is to determine the efficacy of mesenchymal stromal/stem cell (MSC) transplantation therapy on lupus nephritis (LN) and renal function of patients with systemic lupus erythematosus (SLE).</p><p><strong>Methods: </strong>Articles that reported the data of MSC therapy on the renal function as well as disease activity of LN in patients with SLE were searched in PubMed, Web of Science, Embase and the Cochrane Library. Mean difference for disease activity and laboratory parameters were pooled to evaluate the efficacy of MSC, and incidence was pooled for clinical remission, death and severe adverse event.</p><p><strong>Results: </strong>A total of 12 studies with 586 patients were included. The disease activity indices, including SLEDAI and BILAG, were significantly decreased within 12 months after MSC therapy (P< 0.05). Laboratory parameters for renal function and disease control including estimated glomerular filtration rate, creatinine, blood urea nitrogen, complement C3, albumin and urine protein, were also significantly improved after therapy. The pooled rate of clinical remission at 12 months was 28.1% and the total rate during follow-up was 33.7%. The pooled rate of death at 12 months was 5.2% and the total rate during follow-up was 5.5%. Severe adverse events were rare and not associated with the treatment of MSC.</p><p><strong>Conclusions: </strong>This is the first meta-analysis that focuses on the effect of MSC on LN and renal function of patients with SLE, and the results shows a favorable safety profile and encouraging results of MSC for improving the disease activity of LN as well as the renal function of SLE patients.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9804294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of Adherence to Short-Course Probiotics Among Children with Gastroenteritis who are Enrolled in a Clinical Trial. 参加一项临床试验的肠胃炎儿童对短期益生菌依从性的预测因素
IF 0.8 4区 医学 Q3 Medicine Pub Date : 2023-03-26 DOI: 10.25011/cim.v46i1.39560
Katrina F Hurley, Eleanor A Fitzpatrick, Jianling Xie, Sarah Urquhart, Ken J Farion, Serge Gouin, Suzanne Schuh, Naveen Poonai, Stephen Freedman

Background: To improve our understanding of adherence to discharge medications in the ED and within research trials, we sought to quantify medication adherence and identify predictors thereof in children with acute gastroenteritis (AGE).

Methods: We conducted a secondary analysis of a randomized trial of twice daily probiotic for 5 days. The population included previously healthy children aged 3-47 months with AGE. The primary outcome was patient-reported adherence to the treatment regimen, defined a priori as having received >70% of the prescribed doses. Secondary outcomes included predictors of treatment adherence and concordance between patient-reported adherence and the returned medication sachet counts.

Results: After excluding participants with missing data on adherence, 760 participants were included in this analysis: 383 in the probiotic arm (50.4%); and 377 in the placebo arm (49.6%). Self-reported adherence was similar in both groups (77.0% in probiotic versus 80.3% in placebo). There was good agreement between self-reported adherence and sachet counts (87% within limits of agreement (-2.9 to 3.5 sachets) on the Bland-Altman plots). In the multivariable regression model, covariates associated with adherence were greater number of days of diarrhea post-emergency department visit, and the study site; covariates negatively associated with adherence were age 12-23 months, severe dehydration and greater total number of vomiting and diarrhea episodes after enrolment.

Conclusions: Longer duration of diarrhea and study site were associated with higher probiotic adherence. Age 12-23 months, severe dehydration and greater number of vomiting and diarrhea episodes post enrolment negatively predicted treatment adherence.

背景:为了提高我们对急诊科和研究试验中出院药物依从性的理解,我们试图量化急性胃肠炎(AGE)儿童的药物依从性并确定其预测因素。方法:我们对一项随机试验进行了二次分析,该试验每天两次益生菌,持续5天。人群包括先前健康的年龄为3-47个月的AGE儿童。主要结局是患者报告的治疗方案依从性,先验定义为接受了>70%的处方剂量。次要结局包括治疗依从性的预测因子以及患者报告的依从性与退回的药物包计数之间的一致性。结果:在排除依从性数据缺失的参与者后,760名参与者被纳入该分析:益生菌组383名(50.4%);安慰剂组377例(49.6%)。两组自我报告的依从性相似(益生菌组77.0%,安慰剂组80.3%)。在Bland-Altman图中,自我报告的依从性和小袋数之间有很好的一致性(87%在一致性范围内(-2.9到3.5小袋))。在多变量回归模型中,与依从性相关的协变量为急诊科就诊后腹泻天数、研究地点;与依从性负相关的协变量为年龄12-23个月、严重脱水和入组后呕吐和腹泻发作的总次数较多。结论:较长的腹泻持续时间和研究地点与较高的益生菌粘附性相关。年龄12-23个月,入组后严重脱水和更多呕吐和腹泻发作负预测治疗依从性。
{"title":"Predictors of Adherence to Short-Course Probiotics Among Children with Gastroenteritis who are Enrolled in a Clinical Trial.","authors":"Katrina F Hurley,&nbsp;Eleanor A Fitzpatrick,&nbsp;Jianling Xie,&nbsp;Sarah Urquhart,&nbsp;Ken J Farion,&nbsp;Serge Gouin,&nbsp;Suzanne Schuh,&nbsp;Naveen Poonai,&nbsp;Stephen Freedman","doi":"10.25011/cim.v46i1.39560","DOIUrl":"https://doi.org/10.25011/cim.v46i1.39560","url":null,"abstract":"<p><strong>Background: </strong>To improve our understanding of adherence to discharge medications in the ED and within research trials, we sought to quantify medication adherence and identify predictors thereof in children with acute gastroenteritis (AGE).</p><p><strong>Methods: </strong>We conducted a secondary analysis of a randomized trial of twice daily probiotic for 5 days. The population included previously healthy children aged 3-47 months with AGE. The primary outcome was patient-reported adherence to the treatment regimen, defined a priori as having received >70% of the prescribed doses. Secondary outcomes included predictors of treatment adherence and concordance between patient-reported adherence and the returned medication sachet counts.</p><p><strong>Results: </strong>After excluding participants with missing data on adherence, 760 participants were included in this analysis: 383 in the probiotic arm (50.4%); and 377 in the placebo arm (49.6%). Self-reported adherence was similar in both groups (77.0% in probiotic versus 80.3% in placebo). There was good agreement between self-reported adherence and sachet counts (87% within limits of agreement (-2.9 to 3.5 sachets) on the Bland-Altman plots). In the multivariable regression model, covariates associated with adherence were greater number of days of diarrhea post-emergency department visit, and the study site; covariates negatively associated with adherence were age 12-23 months, severe dehydration and greater total number of vomiting and diarrhea episodes after enrolment.</p><p><strong>Conclusions: </strong>Longer duration of diarrhea and study site were associated with higher probiotic adherence. Age 12-23 months, severe dehydration and greater number of vomiting and diarrhea episodes post enrolment negatively predicted treatment adherence.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9804295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spring 2023: Clinician Investigator Trainee Association of Canada (CITAC). 2023年春季:加拿大临床研究员培训协会(CITAC)。
IF 0.8 4区 医学 Q3 Medicine Pub Date : 2023-03-26 DOI: 10.25011/cim.v46i1.39997
Melissa Phuong, Robert Lao, Yujin Suk, Wenxuan Wang, Amelia Yuan

Over the past year, the leadership of the Clinician Investigator Trainee Association of Canada (CITAC), alongside our MD+ trainees, had the opportunity to further develop and implement our strategic plan in response to the evolving medical landscape. We have dedicated our efforts to the progression towards a post-pandemic environment, have taken advantage of the lessons learned during the coronavirus disease 2019 (COVID-19) health crisis and have focused on enhancing in-person career development opportunities for our members.

在过去的一年里,加拿大临床研究员培训协会(CITAC)的领导,以及我们的医学博士+培训生,有机会进一步制定和实施我们的战略计划,以应对不断变化的医疗环境。我们一直致力于向大流行后环境发展,利用2019年冠状病毒病(COVID-19)健康危机期间的经验教训,并专注于为我们的会员增加面对面的职业发展机会。
{"title":"Spring 2023: Clinician Investigator Trainee Association of Canada (CITAC).","authors":"Melissa Phuong,&nbsp;Robert Lao,&nbsp;Yujin Suk,&nbsp;Wenxuan Wang,&nbsp;Amelia Yuan","doi":"10.25011/cim.v46i1.39997","DOIUrl":"https://doi.org/10.25011/cim.v46i1.39997","url":null,"abstract":"<p><p>Over the past year, the leadership of the Clinician Investigator Trainee Association of Canada (CITAC), alongside our MD+ trainees, had the opportunity to further develop and implement our strategic plan in response to the evolving medical landscape. We have dedicated our efforts to the progression towards a post-pandemic environment, have taken advantage of the lessons learned during the coronavirus disease 2019 (COVID-19) health crisis and have focused on enhancing in-person career development opportunities for our members.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9804298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ribavirin Does Not Enhance Hepatitis B Virus Nucleotide Antiviral Activity: A Pilot Study. 利巴韦林不能增强乙型肝炎病毒核苷酸抗病毒活性:一项初步研究。
IF 0.8 4区 医学 Q3 Medicine Pub Date : 2022-12-31 DOI: 10.25011/cim.v45i4.39274
Alexa Keeshan, Carla Coffin, Alicia Vachon, Nishi Patel, Scott Fung, Leanne Mortimer, Angela Crawley, Mang Ma, Carla Osiowy, Curtis Cooper

Purpose: There is a need for effective and affordable treatments that achieve hepatitis B virus (HBV) functional cure and prevent long-term complications. The use of immune-modulators combined with HBV antivirals is a promising therapeutic strategy to achieve these goals. Based on ribavirin (RBV) monotherapy data, we hypothesized that RBV could improve virological responses when used in combination with tenofovir.  Methods: In this randomized, open label, controlled pilot trial, we evaluated RBV (n=4) dosed for the initial 24 weeks of treatment versus no RBV (n=4) in tenofovir recipients dosed over 48 weeks.  Results: Although well tolerated and safe in combination with tenofovir, RBV demonstrated no beneficial effects on virologic, biochemical or immunological markers of chronic HBV infection over 48 weeks of serial evaluation.  Conclusions: Our data does not suggest a HBV-specific immunomodulatory effect or an impact of RBV on HBV virological and antigen suppression.

目的:需要有效和负担得起的治疗方法,以实现乙型肝炎病毒(HBV)功能性治愈并预防长期并发症。使用免疫调节剂联合HBV抗病毒药物是实现这些目标的一种有希望的治疗策略。基于利巴韦林(RBV)单药治疗数据,我们假设RBV与替诺福韦联合使用可以改善病毒学反应。方法:在这项随机、开放标签、对照的试点试验中,我们评估了替诺福韦治疗最初24周时服用RBV (n=4)与48周后服用无RBV (n=4)的替诺福韦受体。结果:尽管RBV与替诺福韦联合使用耐受性良好且安全,但在48周的系列评估中,RBV对慢性HBV感染的病毒学、生化或免疫学标志物没有有益的影响。结论:我们的数据不表明HBV特异性免疫调节作用或RBV对HBV病毒学和抗原抑制的影响。
{"title":"Ribavirin Does Not Enhance Hepatitis B Virus Nucleotide Antiviral Activity: A Pilot Study.","authors":"Alexa Keeshan,&nbsp;Carla Coffin,&nbsp;Alicia Vachon,&nbsp;Nishi Patel,&nbsp;Scott Fung,&nbsp;Leanne Mortimer,&nbsp;Angela Crawley,&nbsp;Mang Ma,&nbsp;Carla Osiowy,&nbsp;Curtis Cooper","doi":"10.25011/cim.v45i4.39274","DOIUrl":"https://doi.org/10.25011/cim.v45i4.39274","url":null,"abstract":"<p><strong>Purpose: </strong>There is a need for effective and affordable treatments that achieve hepatitis B virus (HBV) functional cure and prevent long-term complications. The use of immune-modulators combined with HBV antivirals is a promising therapeutic strategy to achieve these goals. Based on ribavirin (RBV) monotherapy data, we hypothesized that RBV could improve virological responses when used in combination with tenofovir.  Methods: In this randomized, open label, controlled pilot trial, we evaluated RBV (n=4) dosed for the initial 24 weeks of treatment versus no RBV (n=4) in tenofovir recipients dosed over 48 weeks.  Results: Although well tolerated and safe in combination with tenofovir, RBV demonstrated no beneficial effects on virologic, biochemical or immunological markers of chronic HBV infection over 48 weeks of serial evaluation.  Conclusions: Our data does not suggest a HBV-specific immunomodulatory effect or an impact of RBV on HBV virological and antigen suppression.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10609676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hats Off to the CIM Reviewers Of 2022. 向2022年CIM评审员致敬。
IF 0.8 4区 医学 Q3 Medicine Pub Date : 2022-12-31 DOI: 10.25011/cim.v45i4.39559
Robert Bortolussi

For over 40 years the journal of Clinical and Investigative Medicine (CIM) has published articles of interest to clinician investigators in Canada and elsewhere. We strive for the highest standards and to remain relevant to our readers, but we cannot achieve this goal without the help of our reviewers, all of whom play a vital role in maintaining the integrity of the scientific process. Without their efforts, academic excellence would falter.

40多年来,临床和调查医学杂志(CIM)发表了加拿大和其他地方临床研究人员感兴趣的文章。我们力求达到最高标准,并与读者保持联系,但如果没有审稿人的帮助,我们就无法实现这一目标,他们在维护科学过程的完整性方面都发挥着至关重要的作用。没有他们的努力,优秀的学术成就就会动摇。
{"title":"Hats Off to the CIM Reviewers Of 2022.","authors":"Robert Bortolussi","doi":"10.25011/cim.v45i4.39559","DOIUrl":"https://doi.org/10.25011/cim.v45i4.39559","url":null,"abstract":"<p><p>For over 40 years the journal of Clinical and Investigative Medicine (CIM) has published articles of interest to clinician investigators in Canada and elsewhere. We strive for the highest standards and to remain relevant to our readers, but we cannot achieve this goal without the help of our reviewers, all of whom play a vital role in maintaining the integrity of the scientific process. Without their efforts, academic excellence would falter.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10832433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022 Joint Meeting On Transplantation: Canadian Society of Transplantation And Banff Foundation of Allograft Pathology. 2022年移植联合会议:加拿大移植学会和班夫同种异体移植病理基金会。
IF 0.8 4区 医学 Q3 Medicine Pub Date : 2022-12-31 DOI: 10.25011/cim.v45i4.39557
Jeffry Schiff, Michael Mengel

The Canadian Society of Transplantation (CST) annual scientific meeting was held in Banff Alberta September 19-23, 2022. It provided a forum for the transplantation community to share ideas, leading practices, innovative science and educational content in transplant care. The meeting brought together members of the Banff Foundation for Allograft Pathology and the CST for a hybrid event, combining both in-person and virtual experiences, and helping the two societies reach a wider audience. With over 600 Canadian and International delegates attending, the 2022 Banff-CST Meeting received outstanding educational programming, but also rare opportunities to connect with transplantation professionals from all over the world.

加拿大移植学会(CST)年度科学会议于2022年9月19日至23日在阿尔伯塔省班夫举行。它为移植界提供了一个论坛,分享移植护理方面的想法、领先实践、创新科学和教育内容。这次会议将班夫同种异体病理学基金会和CST的成员聚集在一起,进行了一次混合活动,结合了面对面和虚拟的体验,并帮助两个协会接触到更广泛的受众。超过600名加拿大和国际代表参加了2022年班夫- cst会议,不仅获得了出色的教育计划,而且还获得了与来自世界各地的移植专业人士交流的难得机会。
{"title":"2022 Joint Meeting On Transplantation: Canadian Society of Transplantation And Banff Foundation of Allograft Pathology.","authors":"Jeffry Schiff,&nbsp;Michael Mengel","doi":"10.25011/cim.v45i4.39557","DOIUrl":"https://doi.org/10.25011/cim.v45i4.39557","url":null,"abstract":"<p><p>The Canadian Society of Transplantation (CST) annual scientific meeting was held in Banff Alberta September 19-23, 2022. It provided a forum for the transplantation community to share ideas, leading practices, innovative science and educational content in transplant care. The meeting brought together members of the Banff Foundation for Allograft Pathology and the CST for a hybrid event, combining both in-person and virtual experiences, and helping the two societies reach a wider audience. With over 600 Canadian and International delegates attending, the 2022 Banff-CST Meeting received outstanding educational programming, but also rare opportunities to connect with transplantation professionals from all over the world.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10609674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elevated Serum Interleukin-17 Levels in Thoracic Trauma Patients with Poor Prognosis: A Prospective Observational Study. 预后不良的胸外伤患者血清白细胞介素-17水平升高:一项前瞻性观察研究
IF 0.8 4区 医学 Q3 Medicine Pub Date : 2022-12-31 DOI: 10.25011/cim.v45i4.39558
Qiang Wang, Xiaoliu Li, Jing Zhang, Lian Xiang, Jing Dong

Purpose: To measure interleukin (IL)-17 serum levels in thoracic trauma patients and to correlate these levels with other cytokines and with patient prognosis.  Methods: This prospective observational study recruited 130 thoracic trauma patients who were admitted to the Zhoupu Hospital Affiliated to Shanghai Medical College of Health June 2020 to April 2022 and 100 healthy volunteers. Patients were divided into two groups based on Injury Severity Score (ISS): ISS<16 (mild/moderate trauma) and ISS ≥16 (severe trauma). Serum IL-17, tumor necrosis factor α (TNF-α), IL-6, IL-1β and C-reactive protein (CRP) levels were measured by enzyme-linked immunosorbent assay. Patients with poor prognosis were defined as those who developed serious complications or died during hospitalization or follow-up.  Results: Serum levels of IL-17, TNF-α, IL-6 and IL-1β were significantly elevated in patients with ISS ≥16 (p<0.05). Serum cytokines levels increased within 48 h in both groups and then gradually decreased during subsequent treatment and rehabilitation. Pearson's analysis indicated a positive correlation among IL-17, TNF-α and IL-1β. Serum IL-17 levels in patients with poor prognoses were higher than the patients with good prognoses at all time points (p<0.05). Furthermore, for patients with poor prognoses, the serum IL-17 levels had highest diagnostic value among all the cytokines measured. Logistic regression analysis showed that IL-17 was the risk factor for thoracic trauma patients with poor prognoses.  Conclusion: Serum IL-17 levels were significantly elevated in thoracic trauma patients and decreased gradually with rehabilitation. IL-17 was a risk factor for thoracic trauma patients with poor prognoses. This study suggests a new diagnostic and therapeutic target for thoracic trauma patients.

目的:测定胸外伤患者血清白细胞介素(IL)-17水平,并探讨其与其他细胞因子及预后的关系。方法:本前瞻性观察研究招募了2020年6月至2022年4月上海卫生学院附属周浦医院收治的130例胸部外伤患者和100名健康志愿者。根据损伤严重程度评分(ISS)将患者分为两组:ISS
{"title":"Elevated Serum Interleukin-17 Levels in Thoracic Trauma Patients with Poor Prognosis: A Prospective Observational Study.","authors":"Qiang Wang,&nbsp;Xiaoliu Li,&nbsp;Jing Zhang,&nbsp;Lian Xiang,&nbsp;Jing Dong","doi":"10.25011/cim.v45i4.39558","DOIUrl":"https://doi.org/10.25011/cim.v45i4.39558","url":null,"abstract":"<p><strong>Purpose: </strong>To measure interleukin (IL)-17 serum levels in thoracic trauma patients and to correlate these levels with other cytokines and with patient prognosis.  Methods: This prospective observational study recruited 130 thoracic trauma patients who were admitted to the Zhoupu Hospital Affiliated to Shanghai Medical College of Health June 2020 to April 2022 and 100 healthy volunteers. Patients were divided into two groups based on Injury Severity Score (ISS): ISS<16 (mild/moderate trauma) and ISS ≥16 (severe trauma). Serum IL-17, tumor necrosis factor α (TNF-α), IL-6, IL-1β and C-reactive protein (CRP) levels were measured by enzyme-linked immunosorbent assay. Patients with poor prognosis were defined as those who developed serious complications or died during hospitalization or follow-up.  Results: Serum levels of IL-17, TNF-α, IL-6 and IL-1β were significantly elevated in patients with ISS ≥16 (p<0.05). Serum cytokines levels increased within 48 h in both groups and then gradually decreased during subsequent treatment and rehabilitation. Pearson's analysis indicated a positive correlation among IL-17, TNF-α and IL-1β. Serum IL-17 levels in patients with poor prognoses were higher than the patients with good prognoses at all time points (p<0.05). Furthermore, for patients with poor prognoses, the serum IL-17 levels had highest diagnostic value among all the cytokines measured. Logistic regression analysis showed that IL-17 was the risk factor for thoracic trauma patients with poor prognoses.  Conclusion: Serum IL-17 levels were significantly elevated in thoracic trauma patients and decreased gradually with rehabilitation. IL-17 was a risk factor for thoracic trauma patients with poor prognoses. This study suggests a new diagnostic and therapeutic target for thoracic trauma patients.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10609675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
University of Montreal's Clinician-Investigator Program: A 10-Year Descriptive Evaluation. 蒙特利尔大学临床医师-研究者项目:10年描述性评价。
IF 0.8 4区 医学 Q3 Medicine Pub Date : 2022-12-31 DOI: 10.25011/cim.v45i4.39275
Samuel Mailhot-Larouche, Vincent Chauvette, David Bergeron, Catherine Larochelle, Geneviève Du Pont-Thibodeau, Han Wang, Héloïse Cardinal, Isabelle Bourdeau, Nathalie Auger, Nathalie Bureau Md MSc Bureau, Alexandre Prat, Didier Jutras-Aswad, François Madore, Guillaume Emeriaud, Houda Bahig, Marie-Hélène Mayrand, Rafik Tadros, Stefan Parent, Philippe Richebe Md PhD Richebe, Yahye Merhi, Dang Nguyen

Purpose: Clinician-investigators have an important role in the development and implantation of new therapies and treatment modalities; however, there have been several reports highlighting a pending shortage in the clinician-investigators' workforce. In Canada, the Royal College has promoted the development of clinician-investigators programs (CIP) to facilitate the training of these individuals. There is currently a paucity of data regarding the outcomes of such programs. This study aims to identify the strengths and areas of improvement of the Montreal University CIP.  Methods: An internet-based 51-question survey was distributed to all the alumni from the University of Montreal CIP. Participation was voluntary and no incentives were provided. The response rate was 64%.  Results: Among respondents, 50% (n=16) had completed their clinical residency and all CIP requirements. The majority of these individuals (63%) had become independent investigators and had secured provincial and national funding. Satisfaction of the respondents was high regarding the overall program (85%), the research skills developed during the CIP (84%) and the financial support obtained during the program (72%). The satisfaction rate regarding career planning was lower (63%).  Conclusion: This survey demonstrates that, while indicators are favorable, some areas still require improvement. Several steps to improve the CIP have been identified; notably, the transition from the CIP to early independent career has been identified as critical in the development of clinician-investigators and steps have been taken to improve this progression.

目的:临床研究者在新疗法和治疗方式的开发和实施中发挥着重要作用;然而,有几份报告强调了临床研究人员的劳动力短缺。在加拿大,皇家学院促进了临床研究人员计划(CIP)的发展,以促进这些个人的培训。目前缺乏关于这些项目结果的数据。本研究旨在确定蒙特利尔大学CIP的优势和改进领域。方法:采用网络调查的方式,对蒙特利尔大学CIP的所有校友进行问卷调查。参与是自愿的,不提供奖励。应答率为64%。结果:在受访者中,50% (n=16)完成了临床住院治疗和所有CIP要求。这些人中的大多数(63%)已成为独立调查员,并获得了省和国家的资助。受访者对整个计划(85%),在CIP期间发展的研究技能(84%)和在计划期间获得的经济支持(72%)的满意度很高。职业规划满意度较低(63%)。结论:本次调查显示,虽然各项指标较好,但仍有一些领域有待改进。已经确定了改善CIP的几个步骤;值得注意的是,从CIP到早期独立职业的过渡已经被确定为临床研究人员发展的关键,并且已经采取措施来改善这一进展。
{"title":"University of Montreal's Clinician-Investigator Program: A 10-Year Descriptive Evaluation.","authors":"Samuel Mailhot-Larouche,&nbsp;Vincent Chauvette,&nbsp;David Bergeron,&nbsp;Catherine Larochelle,&nbsp;Geneviève Du Pont-Thibodeau,&nbsp;Han Wang,&nbsp;Héloïse Cardinal,&nbsp;Isabelle Bourdeau,&nbsp;Nathalie Auger,&nbsp;Nathalie Bureau Md MSc Bureau,&nbsp;Alexandre Prat,&nbsp;Didier Jutras-Aswad,&nbsp;François Madore,&nbsp;Guillaume Emeriaud,&nbsp;Houda Bahig,&nbsp;Marie-Hélène Mayrand,&nbsp;Rafik Tadros,&nbsp;Stefan Parent,&nbsp;Philippe Richebe Md PhD Richebe,&nbsp;Yahye Merhi,&nbsp;Dang Nguyen","doi":"10.25011/cim.v45i4.39275","DOIUrl":"https://doi.org/10.25011/cim.v45i4.39275","url":null,"abstract":"<p><strong>Purpose: </strong>Clinician-investigators have an important role in the development and implantation of new therapies and treatment modalities; however, there have been several reports highlighting a pending shortage in the clinician-investigators' workforce. In Canada, the Royal College has promoted the development of clinician-investigators programs (CIP) to facilitate the training of these individuals. There is currently a paucity of data regarding the outcomes of such programs. This study aims to identify the strengths and areas of improvement of the Montreal University CIP.  Methods: An internet-based 51-question survey was distributed to all the alumni from the University of Montreal CIP. Participation was voluntary and no incentives were provided. The response rate was 64%.  Results: Among respondents, 50% (n=16) had completed their clinical residency and all CIP requirements. The majority of these individuals (63%) had become independent investigators and had secured provincial and national funding. Satisfaction of the respondents was high regarding the overall program (85%), the research skills developed during the CIP (84%) and the financial support obtained during the program (72%). The satisfaction rate regarding career planning was lower (63%).  Conclusion: This survey demonstrates that, while indicators are favorable, some areas still require improvement. Several steps to improve the CIP have been identified; notably, the transition from the CIP to early independent career has been identified as critical in the development of clinician-investigators and steps have been taken to improve this progression.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10602833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Value Of Anteroposterior-To-Transverse Ratio in Ultrasonic Diagnosis of Thyroid Nodule in Different Locations. 超声正横比对不同部位甲状腺结节的诊断价值。
IF 0.8 4区 医学 Q3 Medicine Pub Date : 2022-12-31 DOI: 10.25011/cim.v45i4.38877
Hai-Ning Zheng, Wei Wang Md Wang, Xiao-Qing Wang Md Wang, Wen-Jing Song, Wen-Jing Song, Rui Zhao, Meng Li, Chao-Yang Wen Md Wen

Purpose: To investigate the value of anteroposterior-to-transverse ratio (ATR) and the effect on features of nodules in ultrasound (US) diagnosis of thyroid nodules in different locations.  Methods: The nodules were divided into three groups according to the different nodule location: isthmus group; upper and lower poles of bilobed thyroid group; and the middle of the bilobed thyroid group. The diameters of the nodules were recorded, and ATR of the nodule was calculated on the transverse and longitudinal sections. The transverse and the longitudinal sections of ATR of thyroid nodules in different groups were compared.  Result: The transverse section of ATR was significantly different among the three groups (p = 0.001). In addition, there are significant differences in many US features among three groups, including nodule composition, thyroid parenchyma, morphology, echogenicity, shape, calcifications, vascularity, nodule ACR TI-RADS and histopathologic (all p < 0.05). In the group of upper and lower poles of bilobed thyroid, significant difference was found between the transverse and the longitudinal section of ATR (p = 0.019). The cut-off values of transverse section and longitudinal section of ATR were 0.967 and 0.750, respectively.  Conclusion: The transverse section of ATR at different location of thyroid may be a predictor for malignancy with clinical diagnostic significance.

目的:探讨正横比(ATR)在不同部位甲状腺结节超声诊断中的价值及对结节特征的影响。方法:根据结节位置的不同将结节分为三组:峡部组;双叶状甲状腺群上、下两极;还有中间的双叶状甲状腺。记录结节直径,在横切面和纵切面计算结节的ATR。比较不同组甲状腺结节的ATR横切面和纵切面。结果:三组间ATR横切面差异有统计学意义(p = 0.001)。此外,三组在结节组成、甲状腺实质、形态学、回声性、形状、钙化、血管、结节ACR、TI-RADS、组织病理学等诸多US特征上均存在显著差异(p < 0.05)。在双叶甲状腺上、下两极组,ATR横切面与纵切面差异有统计学意义(p = 0.019)。ATR横切面和纵切面的截止值分别为0.967和0.750。结论:甲状腺不同部位ATR横切面可作为恶性肿瘤的预测指标,具有临床诊断意义。
{"title":"Value Of Anteroposterior-To-Transverse Ratio in Ultrasonic Diagnosis of Thyroid Nodule in Different Locations.","authors":"Hai-Ning Zheng,&nbsp;Wei Wang Md Wang,&nbsp;Xiao-Qing Wang Md Wang,&nbsp;Wen-Jing Song,&nbsp;Wen-Jing Song,&nbsp;Rui Zhao,&nbsp;Meng Li,&nbsp;Chao-Yang Wen Md Wen","doi":"10.25011/cim.v45i4.38877","DOIUrl":"https://doi.org/10.25011/cim.v45i4.38877","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the value of anteroposterior-to-transverse ratio (ATR) and the effect on features of nodules in ultrasound (US) diagnosis of thyroid nodules in different locations.  Methods: The nodules were divided into three groups according to the different nodule location: isthmus group; upper and lower poles of bilobed thyroid group; and the middle of the bilobed thyroid group. The diameters of the nodules were recorded, and ATR of the nodule was calculated on the transverse and longitudinal sections. The transverse and the longitudinal sections of ATR of thyroid nodules in different groups were compared.  Result: The transverse section of ATR was significantly different among the three groups (p = 0.001). In addition, there are significant differences in many US features among three groups, including nodule composition, thyroid parenchyma, morphology, echogenicity, shape, calcifications, vascularity, nodule ACR TI-RADS and histopathologic (all p < 0.05). In the group of upper and lower poles of bilobed thyroid, significant difference was found between the transverse and the longitudinal section of ATR (p = 0.019). The cut-off values of transverse section and longitudinal section of ATR were 0.967 and 0.750, respectively.  Conclusion: The transverse section of ATR at different location of thyroid may be a predictor for malignancy with clinical diagnostic significance.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10609678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Investigative Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1